Poseida Therapeutics has appointed Martin Giedlin, Ph.D., as vice president, technical operations.   Dr. Giedlin brings more than 20 years of experience supporting immunotherapy options for cancer and infectious disease through the development of recombinant proteins, monoclonal antibodies, gene therapy and vaccines. He most recently served as executive director, process sciences, in Novartis Pharmaceuticals’ Cell and Gene Therapy group that focused on gene-editing of autologous T cells....